home / stock / apre / apre news

APRE News and Press, Aprea Therapeutics Inc. From 10/24/23

Stock Information
Company Name: Aprea Therapeutics Inc.
Stock Symbol: APRE
Market: NASDAQ
Website: aprea.com
Menu
APRE APRE Quote APRE Short APRE News APRE Articles APRE Message Board
Get APRE Alerts

News, Short Squeeze, Breakout and More Instantly...
APRE - Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways

DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tue...
APRE - Palatin Technologies, Protalix BioTherapeutics, Arcutis among healthcare movers

2023-10-20 10:06:59 ET More on Health Care: Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the...

APRE - Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

DOYLESTOWN, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced highlights of two posters prese...

APRE - Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

DOYLESTOWN, Pa., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced two poster presentations at th...
APRE - Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Demonstrating potential safety and efficacy of WEE1 inhibitor, ATRN-1051, in the treatment of ovarian cancer Company anticipates submitting an IND by the end of 2023 Data to be presented at an upcoming 2023 scientific conference, with KOL event planned for the fall DOYLEST...

APRE - Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

DOYLESTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad, Ph.D., Preside...

APRE - Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

DOYLESTOWN, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it has appointed Dr. Jean-Pierr...
APRE - Aprea Therapeutics shows Q2 results

2023-08-10 10:35:44 ET Aprea Therapeutics press release ( NASDAQ: APRE ): Q2 GAAP EPS of -$0.87. Revenue of $250K. As of June 30, 2023, the company reported cash and cash equivalents of $27.7 million. For further details see: Aprea Therapeutics shows Q2 results

APRE - Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the t...

APRE - TOST, GP and GNPX among pre-market losers

2023-07-19 08:30:52 ET Aqua Metals ( AQMS ) -27% after disclosing stock offering . Amarin Corporation ( AMRN ) -20% on plan to undergo restructuring . Biophytis ( BPTS ) -18% on $3.8M offering . Genprex ( GNPX ) -14% on $7.5 Millio...
Previous 10 Next 10